Actelion
| Actelion Ltd
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0010532478 |
| founding | 1997 |
| Seat | Allschwil , Switzerland |
| management | Jean-Paul Clozel Chief Executive Officer Jean-Pierre Garnier ( Chairman of the Board of Directors ) |
| Number of employees | 2,547 (2015) |
| sales | 2.042 billion. CHF (2015) |
| Branch | pharmacy |
| Website | www.actelion.com |
Actelion Pharmaceuticals Ltd or Actelion Ltd is a Swiss pharmaceutical company with headquarters in Allschwil in the canton of Basel-Landschaft . The company specializes in the development and sale of endothelial- related active ingredients.
In January 2017, the US company Johnson & Johnson made a takeover offer for Actelion in the amount of 30 billion US dollars. The takeover was completed in June 2017.
Key figures
In January 2015, the company employed a total of 2,547 people, 371 of them in research, 422 in development and 1,425 in marketing and sales. In 2015 Actelion generated sales of 2.042 billion Swiss francs.
Actelion was founded in December 1997. Cardiologist Jean-Paul Clozel is the founder and chairman of the executive board . After Actelion on the Swiss Exchange SWX Swiss Exchange since 2000 in the Swiss Leader Index of thirty liquidate most representative and largest Swiss stocks listed was, the company was also in the per September 22, 2008 Swiss Market Index added. In the course of the takeover by Johnson & Johnson, Actelion dropped out of the SMI and SLI again in 2017.
The company has branches in over 20 countries (Australia, Belgium, Brazil, Germany, France, Greece, Israel, Italy, Japan, Canada, Korea, Netherlands, Austria, Portugal, Sweden, Switzerland, Spain, Czech Republic, Turkey, USA, United Kingdom). The German branch is in Freiburg im Breisgau , the Austrian in Vienna .
Products
Products developed by Actelion and already on the market are the orphan drugs :
- Tracleer ( bosentan ): an endothelin receptor antagonist used to treat pulmonary arterial hypertension
- Zavesca ( miglustat ): an inhibitor of the enzyme glucosylceramide - synthase (glucosylceramide is a cerebroside - derivative ) for the treatment of mild to moderate cases of Gaucher disease type I
- Opsumit ( Macitentan ): an endothelin receptor antagonist used to treat pulmonary arterial hypertension
Among other things, Actelion markets the drug developed by Schering AG in the USA
- Ventavis ( iloprost ): a prostacyclin analogue for inhalative therapy of primary pulmonary hypertension (NYHA III)
Web links
- Actelion Pharmaceutical Ltd website , English
Individual evidence
- ↑ a b c d e f Actelion: Actelion Fact Sheet (PDF) 2016. Accessed February 9, 2016.
- ↑ a b Actelion: Actelion Executive Committee . 2016. Archived from the original on February 9, 2016. Retrieved on February 9, 2016.
- ↑ a b Actelion: Actelion presents outstanding 2015 results . February 9, 2016. Archived from the original on February 9, 2016. Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. Retrieved February 9, 2016.
- ^ Johnson & Johnson wants to buy Actelion , Neue Zürcher Zeitung , January 26, 2017
- ↑ Johnson & Johnson Completes Acquisition of Actelion ( Memento of the original from December 31, 2017 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , Actelion PM dated June 16, 2017, accessed June 16, 2017
- ↑ JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $ 30 BILLION WITH SPIN- OUT OF NEW R&D COMPANY ( Memento of the original dated February 7, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. PM J&J of January 26, 2017, p. Roadmap, accessed February 7, 2017
- ↑ Actelion: Actelion Fact Sheet Marketed Product (PDF) 2014. Archived from the original on February 24, 2014. Retrieved on February 11, 2014.
